NEW YORK, Nov. 20, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, today announced that the Company's Board of Directors approved the purchase of up to $1 million in Bitcoin."As Bitcoin continues to grow, gaining investor attention and acceptance as a major and primary asset class, we believe that Bitcoin will serve as a strong treasury reserve asset," said Robb Knie, CEO of Hoth. "With recent approval of Bitcoin ETFs and increasing activity from ins ...

Research and Development Expenses - Research and development expenses decreased by $77,000 (7.9%) for the three months ended September 30, 2024 compared to the same period in 2023[134] - Research and development expenses for the three months ended September 30, 2024 were $0.9 million, with $0.6 million allocated to HT-001, $154,300 to HT-KIT, $18,700 to HT-004, and $96,500 to HT-ALZ[135] - Research and development expenses decreased by $635,700 (24.8%) for the nine months ended September 30, 2024 compared to the same period in 2023[141] - Research and development expenses for the nine months ended September 30, 2024 were $1.9 million, with $1.2 million allocated to HT-001, $112,800 to HT-ALZ, $363,300 to HT-KIT, and $96,100 to HT-004[142] General and Administrative Expenses - General and administrative expenses increased by $116,100 (10.4%) for the three months ended September 30, 2024 compared to the same period in 2023[138] - General and administrative expenses increased by $473,500 (13.8%) for the nine months ended September 30, 2024 compared to the same period in 2023[144] Net Loss - Net loss for the three months ended September 30, 2024 was $2.1 million, a decrease of $45,500 compared to the same period in 2023[141] - Net loss for the nine months ended September 30, 2024 was $5.8 million, a decrease of $0.3 million compared to the same period in 2023[150] Cash and Capital Resources - As of September 30, 2024, the company had $8.0 million in cash and cash equivalents and working capital of $7.4 million[151] - The company issued 2,500,000 shares of common stock for net proceeds of $3.8 million during the nine months ended September 30, 2024[152] - Issued new unregistered warrants to purchase up to 3,750,000 shares of common stock at $1.50 per share, expiring on July 3, 2028[154] - Potential milestone payments of up to approximately $10.5 million if all milestones in current agreements are achieved[155] - Net cash used in operations for the nine months ended September 30, 2024, was approximately $5.0 million, primarily due to a net loss of $5.8 million[157] - Net cash provided by financing activities for the nine months ended September 30, 2024, was approximately $3.7 million, resulting from net proceeds from the exercise of warrants[159] - Net cash provided by financing activities for the nine months ended September 30, 2023, was approximately $11.3 million, from the issuance of common stock and warrants[160] Stock-Based Compensation and Valuation - The company estimates the fair value of stock option grants using the Black-Scholes option pricing model, involving inherent uncertainties and management's judgment[164] - Restricted stock awards vest over a service period of zero to three years, with stock-based compensation expense recognized on a straight-line basis[167] - Warrants issued to non-employees vest over a term of zero to ten years, with stock-based compensation expense recognized on a straight-line basis[168] Accounting Standards and Disclosures - The company is evaluating the impact of ASU 2023-09 on income tax disclosures, effective for annual periods beginning after December 15, 2024[171] - The company has a single reportable segment and is evaluating the impact of ASU 2023-07 on segment reporting disclosures, effective for fiscal years beginning after December 15, 2023[175]

NEW YORK, Oct. 29, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company dedicated to developing new generation therapies for unmet medical needs, is excited to announce highly promising early data from a preclinical study of its latest cancer treatment. The preliminary results demonstrate that the treatment successfully stabilizes tumor growth with remarkable consistency across subjects, showing potential as an effective therapeutic option in oncology. This ...

NEW YORK, Oct. 15, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing innovative treatments, is proud to announce the granting of a U.S. patent for its pioneering Alzheimer's treatment, HT-ALZ. This milestone patent secures the company's intellectual property rights to its novel therapeutic approach, as Hoth accelerates preparations for clinical trials. HT-ALZ represents a breakthrough in Alzheimer's treatment, specifically targeting ...

Early observations suggest that the vehicle-treated Alzheimer's mice exhibit a larger population of reactive astrocytes, while the HT-ALZ treated groups show fewer reactive astrocytes, pointing to a potential breakthrough in the treatment of Alzheimer's. NEW YORK, Sept. 17, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on developing innovative treatments for unmet medical needs, today announced encouraging preclinical results for its investigational Alzheim ...

Shares of Hoth Therapeutics (HOTH) surged 81.4% on Sept. 5, after the company announced positive data from the treatment of the first patient with its lead candidate, HT-001, who was experiencing papulopustular eruptions (PPEs). Notably, PPEs are a common and debilitating side effect of EGFR inhibitor (EGFRI) therapy in cancer patients. Hoth's HT-001 Demonstrates Superior Efficacy in PPEs Treatment In this groundbreaking case, the 59-year-old female patient undergoing treatment for metastatic breast cancer ...

Dana-Farber Cancer Institute in Boston, MA and Montefiore Medical Center in New York, NY Join Clinical Trial NEW YORK, Sept. 5, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced today that it has received Institutional Review Board approval from the Montefiore Medical Center and the Dana-Farber Cancer Institute to proceed with its First-in-Human (FIH) Phase 2a clinical trial of HT-001 for the treatment of skin toxicities associated with ...

Core Insights - Hoth Therapeutics, Inc. announced positive data from a case study involving its novel therapy HT-001 for managing epidermal growth factor receptor inhibitor (EGFRI) associated papulopustular eruptions (PPEs) in cancer patients [2][5] - The therapy demonstrated rapid symptom relief, allowing a 59-year-old female patient to cease treatment after just one week due to significant improvement [4][5] - HT-001 addresses a common side effect of EGFRI treatments, which can affect up to 90% of patients, potentially improving the quality of life for those undergoing cancer therapy [3][5] Company Overview - Hoth Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies to meet unmet medical needs and improve patient quality of life [6] - The company is currently conducting a Phase 2a clinical trial to further evaluate the efficacy and safety of HT-001 in managing EGFRI-associated skin toxicities, with multiple clinical sites involved [5] Industry Context - EGFRIs are widely used in treating various epithelial-origin cancers but are often associated with significant cutaneous side effects, leading to treatment interruptions [3] - The introduction of HT-001 represents a potential breakthrough in managing these side effects, which can cause discomfort and impact ongoing cancer treatments [3][5]

Hoth Therapeutics (NASDAQ:HOTH) stock is on the move Wednesday after the clinical-stage biopharmaceutical company announced a new partnership with LTS Therapy Systems. The agreement with LTS Therapy Systems will see it handle the production of the HT-ALZoral film prototype. This will aid Hoth Therapeutics as it seeks a future Investigational New Drug (IND) Application for clinical trials of the drug. How This Affects HOTH Stock Investors will want to keep reading for more of the most recent stock market sto ...

This press release includes forward-looking statements based upon Hoth's current expectations, which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties, and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing ...